Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 DNA Vaccination in CML and AML
NCT01334060Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Feb 2011
- Primary completion
- Feb 2013
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 DNA vaccine in chronic myeloid leukemia (CML), acute myeloid leukemia (AML), sponsored by University Hospital Southampton NHS Foundation Trust. Started Feb 2011; status: completed.
02
Drugs
WT1 DNA vaccine
03
Conditions
chronic myeloid leukemia (CML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01334060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01334060.